Research Study Summary
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Inflammatory bowel diseases, including ulcerative colitis, are chronic relapsing disorders characterized by destructive inflammation and epithelial injury in the gastrointestinal tract. This study will evaluate the efficacy of intravenous (IV) ustekinumab in inducing clinical remission in subjects with moderately to severely active ulcerative colitis.
To Learn more
CW ID: 214279
Date Last Changed:
May 17, 2016
Clinical Trial Snapshot
- Both Male and Female
- 18 and up
- Overall Status
- Facility Type
- Defined moderately to severely active ulcerative colitis, as defined by a Mayo score of 6 to 12.
- Must not be at imminent risk of colectomy
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.